Introduction: Coronaviruses, RNA viruses infecting various hosts, include severe strains like SARS-CoV and MERS-CoV, causing serious respiratory symptoms. Convalescent plasma therapy, using antibodies from recovered patients, has shown promise in reducing COVID-19 mortality and ICU needs.This study explores key aspects of convalescent plasma therapy and its potential effectiveness in treating COVID-19. Material and methods: The observational study at Netaji Subhash Chandra Bose Medical College, Jabalpur (Jan 2021 - Jun 2022), involved 40 COVID-19 patients. Inclusion criteria followed ICMR guidelines. Data on demographics, clinical parameters, and inflammatory markers were analyzed using SPSS/R. Ethical approval and informed consent were obtained. Results: The study involved 40 participants aged 20-80 years, 55% of whom were 40-60 years old. Males constituted 70%, and blood group 'B' positive was most common (35%). Comorbidities included diabetes (10%), mixed (5%), and hypertension (15%). Fever (62.5%), dyspnea (55%), and weakness (37.5%) were prevalent symptoms. Post-transfusion, D-dimer levels significantly increased. Among 36 on oxygen, 7 improved, 3 shifted to BIPAP, and 1 needed ventilation. No anaphylactic or febrile reactions occurred. Mortality was 83.33% among those with comorbidities. Overall, 52.5% were discharged, while 47.5% died. Conclusion: The study assessed convalescent plasma's impact on 40 COVID-19 patients, noting improvements primarily in those without comorbidities. It significantly raised D-dimer levels but showed minor changes in CRP levels. Mortality was notably higher among comorbid patients (83.33%). Of the total, 52.5% were discharged, and 47.5% succumbed, with no reported anaphylactic or febrile reactions. More research is warranted to refine convalescent plasma therapy, especially for complex cases.